Texas § 1003.053 PATIENT ELIGIBILITY.

Texas Statutes

§ 1003.053 — PATIENT ELIGIBILITY.

Texas § 1003.053

Code HSHealth and Safety Code

This text of Texas § 1003.053 (PATIENT ELIGIBILITY.) is published on Counsel Stack Legal Research, covering Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Tex. Health and Safety Code Code Ann. § 1003.053 (2026).

Text

Sec. 1003.053. PATIENT ELIGIBILITY. A patient is eligible to access and use an investigational stem cell treatment under this subchapter if:

(1)the patient has a severe chronic disease or terminal illness listed in the rules adopted under Section 1003.052 and attested to by the patient's treating physician; and

(2)the patient's physician:

(A)in consultation with the patient, has considered all other treatment options currently approved by the United States Food and Drug Administration and determined that those treatment options are unavailable or unlikely to alleviate the significant impairment or severe pain associated with the severe chronic disease or terminal illness; and

(B)has recommended or prescribed in writing that the patient use a specific class of investigational stem cell

Free access — add to your briefcase to read the full text and ask questions with AI

Sec. 1003.053. PATIENT ELIGIBILITY. A patient is eligible to access and use an investigational stem cell treatment under this subchapter if:
(1) the patient has a severe chronic disease or terminal illness listed in the rules adopted under Section 1003.052 and attested to by the patient's treating physician; and
(2) the patient's physician:
(A) in consultation with the patient, has considered all other treatment options currently approved by the United States Food and Drug Administration and determined that those treatment options are unavailable or unlikely to alleviate the significant impairment or severe pain associated with the severe chronic disease or terminal illness; and
(B) has recommended or prescribed in writing that the patient use a specific class of investigational stem cell treatment.